like to see the prediction from senti, doc logic, kabu, and biosect. Mine is $50.

I am not sure how Raf thinks it is a possibility now but I think KM should go this Authorized Generic AG route without any further delay. This is the faster way to tackle and remove the generics in due course. Marjacs Rule 60 will finally return the Marine patents which is still good while the US patients can continue to enjoy cheap AG Vascepa. If PFE buys us out, they know how to sell AG Vascepa next to their AG Lipitor, pending only to combo them and sell a one pill a day combo Rx one. I see it can happen but how soon?

Nick, thanks very logical; when was it written.

Also, if ATL or someone else comes up with a comparison table for the new secondary endpoint rGBM like he did for the new Primary endpoint nGBM which is very useful, that would be immensely valuable.

$NWBO: The new #DCVax Phase 3 trial Primary Endpoint is: "compare overall survival between patients randomized to DCVax-L & control patients from comparable, contemporaneous trials who received SOC, in patients with newly diagnosed Glioblastoma". I updated my comparison Table: pic.twitter.com/bzgpUrgN51

— ATLnsider (@ATLnsider) December 13, 2020

Above $1 sojo? today?? Ok, we will get there! Give us an hour please.

ok got it sojo! Ready set go!!

'It will go right back up' even before the News.

wow North will be with you. Wonderful. Finally God has put his sight on us.

PM, that point number 1 that Jack said is very true. We experienced in AMRN as well. AF and MH in the name of the so called journalists who had early access to the TLD, released a hit piece right after Dr. Bhatt presented the results in a cardio conference spewing doubts on the efficacy because they claimed the placebo was bad to the patients that helped the treatment arm upping efficacy. The stock price crashed in the next few weeks from the high of 26s to the teens. You are seeing that AF is still bad mouthing on NWBO whenever he gets a chance.

no no no; you are mistaken. One can buy all the shares they want from the open market cheap now. But we are true Americans, loyalists to the Company, that I am talking about 'supporting' the Company which they may not need from us while the BPs might be invading them cutting all kind of deals including b/o what not when TLD is out. We have quite a conviction this trial is quite a success.

Kabu, I like to tell you that me and my minions will again be supporting the Company with both hands once they can sell shares. They said they will do once TLD is out. We will be buying next to Fife et al if we can get an opportunity. Hope Fife and Biggers don't empty the available shares.

MI D says on the tote bag that could very well be a Coming Soon ad. I saw Amarin restricted themselves branding to CVD population when their Anchor trial was in a limbo afraid of sanctions by the FDA. No matter what the DcVaxL is science is quite compelling and the 2018 JTM paper is all the telling already. I bet we already met at least two endpoints and we are going to go thru the roof!

Great Sojo, I always wonder how you are balanced and wise all the time. Nothing has changed in the narrative, nor the science of DcVaxL. The shorts are taking advantage of the Quiet Period to fud and short non stop. We don't know what is really happening behind the curtain. Hope the Quiet Period turns out to be quite good for us, the longs, pretty soon.

Correct. 1) There is no Prior Art. And 2) it is not obvious meaning if you combine DcVaxL with Keytruda, the cancer patient can get better. Thse two things need to stand valid. Looks like the UCLA combo works that the Company must have added this new data in their appeal filing today.

This is a good thing. There is I think proof they have from the UCLA combo trial that our drug DcVaxL helps when combined with the Checkpoint Inhibitors (Keytruda). We will get the patent approved, imo.

This Notice of Appeal was filed by NW et al today in response to the non-final rejection received on 6/14/21. Most patent applications go thru non-final rejection(s) before approval. As long as it was not a final rejection, I guess we are good.

I think so ae k; MRK is in our pocket now.

fantastic flipper, what is the patent application number? We are getting the combo patent?? Notice of Appeal filed just today; extension granted just today. Super!

we want to take it to 81c+. Lets see how it goes.

Thanks flipper. They said anticipating MHRA cert by the end of this month and we still have 20 more days. We were just bamboozled while nothing has changed related to the Company and the data/Quit period from 6 months ago, 3 months ago, and yesterday.

Thanks hyperopia! Beautiful as your eyes opening us up. I see now how FW fits in the scaling up production. I bet they are done put together such servo lines assembly lines to make the system ready for commercial testing. And why not get that certified by the MHRA. Bingo!

yes same kind of comments from me but first a big thanks to smokey for putting together this 4 page document such a nice useful one that I already shared with my minions. Yes, adding Flaskworks discussion to the point of what Kabu shared with us today would be very helpful in terms of meeting the demand or showing the manufacturing capacity like the FDA / MHRA certs as the regulators require. Also explain the difference bet Keytrudas and DcvaxL a bit more like CIs allow the patients weakened dc cells to attack the tumor but in some trigger the lethal autoimmune disease whereas DcVaxL is already mixed with the tumor proteins to do the job with no such toxicities.

Most of my minions are still in gains because I got them Company shares directly with warrants, but some who couldn't participate in the Company dealings, bought shares from the open market and those are under water now.

Overall, again a big thanks to Smokey.

sukus, I know you know there is very little manual handlings involved in the flaskworks approach. It means less contamination and consistent reproducibility are ensured. I don't know how they do the compatibility testing. Is it on the same tumor? how do they compare the efficacy, on the same human? for how long?? I think the compatibility testing should involve only the quality and quantity of the dc cells from the flaskwork and the Cognate method. I am very ignorant in this subject. Sorry to ask you.

I think that the whole checkmate 548 trial was testing that idh 1 mutant population to see whether their Checkpoint Inhibitor helps.

Alright, thanks sojo! Building enough thrust to go vertical I guess.

Doc logic, I am a big fan of your Best Wishes posts. Such a conviction you got that NWBO is your only biotech holding, shame on me, I still have some of that cursed AMRN options in my portfolio which is about 3% of my holdings; rest is all NWBO. But I started trading AMRN first and I couldn't give up on that. I love that drug Vascepa.

'with the news, it will go right back up' and beyond Nick. I think LG got the news; otherwise how could he obtain 15M at this stage. Just hang in there to enjoy all the money we ae going to see. I won't be surprised if the Sawston cert brings 11.4+ by the end of this month.

well said thermo; thanks for a couple of posts from you today. Please do come as often as time permits you.

Me and a number of my minions have >90% of our portfolio in NWBO; we saw 3 times worth, paper money, a year ago; we are still holding and adding/moving forward. We didn't lose sleep, because we have quite a conviction in the Science; recall LL said she believes 'the Science is going to survive' in her Asian Hall Of Fame acceptance speech. While in a Quiet period, what more she can say. We are just sitting tight crossing our fingers for a grand approval of the therapy in all 4 RAs - I think that's what the quiet period is all about - a confidential review process on ORBIS, imo.

The blended OS DcVaxL numbers are still better than the BMY numbers. Plus you have to include the long tail being built after 2018. Weller is not a honest person when it comes to DcVaxL that everyone in the industry is aware of. I never heard ~32months OS by SOC in GBM before. Have you?

see flipper's response

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167004694

My nephew who is a surgeon made a good co(r)n field bear stew during our Thanksgiving gettogether for a 50 of us. It turned out very tasty.

Yes Turner, I always ask myself why LP gave away a billion dollar Cognate and staying with NWBO. The answer in my view is Cognate needs NWBO for its business and NWBO is worth multi billons if not a trillion like AAPL/TSLA or MSFT, imo. Shorts are saying Cognate is CDMO and will generate business on its own from some other bios but not NWBio because they fud DcVaxL is no good. I think CRL is not that stupid buying Cognate out hoping for other businesses; I am sure they saw DcVaxL data under an NDA and all existing contracts carry forwarded agreed on, job well done. Otherwise who are the other cell based bios that can give that much business to Cognate/CRL? CAR-T makers? I can't find any who doesn't have their own cell therapy capacity already in that space. LP is giving out all the clues like 'accelerated', and FDA is signaling more and more favorable guidance to an extent that WHO redefined GBM which is very very favorable for DcVaxL. The icing on the cake is FDA staff supported that EC paper published in the Lancet. The Company got enough money and thus LP et al are determined to take DcVaxL to the patients. Thanks to him that does anyone think John Fife did not see these positives before he loaned ~30M to the Company to date? 'The share price will go right back up with the news'.

ATL has also been kept telling us that this binding agreement is still alive as the timelines of the agreement hasn't expired yet. Why do the bears care if we need CRL or not while they always claim the trail failed, LoL.

We are in the accelerated mode while NVCR is decelerated rapidly; coming weeks might show the difference much more, imo.

The OS number you were quoting for DcVaxL is still a blended number that includes the placebos; plus you might be quoting it from the 2018 JTM paper. It is almost 2022 now that OS must have improved quite a bit, imo. Stop fuding.

Thanks biosect, crystal clear. Commercial production of DcVaxL hasn't started yet and I bet CRL paid a billion dollar to acquire Cognate based on this agreement that they can make more money manufacturing DcVaxL for NWBio once regulatory approval is obtained which they were hoping could happen by the end of Q4 2021 when they acquired Cognate. No wonder like Ex, JC why he selectively ignored this binding agreement bet Cognate and NWBio. Bears are no fair.

I think the helmet scam is widely exposed. Down 10%.
https://finance.yahoo.com/quote/NVCR?p=NVCR&.tsrc=fin-srch

Also CVM is getting done
https://finance.yahoo.com/quote/CVM?p=CVM&.tsrc=fin-srch

All those market cap will come to us eventually. Go NWBO!

scotty, did u see it? See this approach by Boynton/Liau has become a basic science in natural immunotherapy. This can be applied as long as all the viruses are addressed in the personalized dc cells. How neat it is.

https://clinicaltrials.gov/ct2/show/NCT04685603

https://clinicaltrials.gov/ct2/show/NCT04685603

see they went silent on at least 3 things after they talked about it at least once: 1) ORBIS/RMAT/Accelerated Approval/Fast Track 2)BLA development using consultants 3)Flaskworks testing in the summer. I think silent and quiet are both the same. No wonder Quiet Period encompasses these things.